FLURIZAN™ Alzheimer's Disease Phase 3 Clinical Trial (US)
A
Clinical Trial to
Evaluate Aβ42
Reduction for Limiting the
Impact of Alzheimer's
Disease
| Experimental Drug: |
FLURIZAN tarenflurbil |
| Therapeutic Area: |
Alzheimer's Disease |
| Current Status: |
Phase 3 Enrollment is Complete |
Enrollment Status
Enrollment for the U.S. phase 3 study is complete.
Trial Description/Purpose
Enrollment is complete for Myriad's U.S. Phase 3 trial of FLURIZAN in patients with mild Alzheimer's disease (MMSE 20-26).
The Phase 3 study is a double blind, placebo-controlled trial, with
randomization of patients at enrollment into one of two arms. Patients
will be given 800mg of FLURIZAN or placebo twice daily for the
duration of the 18-month study period. Patients may be taking approved
medication for Alzheimer's disease provided the dose has been stable
for at least 6 months. The study is designed to determine FLURIZAN's
ability to alter the course of cognitive decline and functional change
in patients with mild Alzheimer's disease, as measured by the ADAS-cog
(Alzheimer's Disease Assessment Scale, cognitive subscale) test, and
the change in ADCS-ADL (Alzheimer's Disease Cooperative Study -
Activities of Daily Living scale), respectively. Patients who complete 18 months of the study may be eligible for treatment with Flurizan under an open-label protocol.
Contact Information
For more information about FLURIZAN phase 3 clinical trials, please email the team at alzheimerstrials@myriad.com.
|
